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INTRODUCTION
Stroke and transient ischemic attack (TIA) are the most com-
mon neurologic manifestations of antiphospholipid syn-
drome (APS).1,2 APS is suspected when a young patient pres-
ents with thrombotic stroke with no overt risk factors for 
cerebrovascular disease. The most recent international con-
sensus criteria for APS classification (revised Sapporo criteria) 
require persistently positive results for antiphospholipid anti-
bodies (aPL) on two or more occasions at least 12 weeks apart 
and a medium or high titers of anticardiolipin antibody (aCL) 
or anti-β2-glycoprotein-1 (anti-β2-GPI) antibody in associa-
tion with clinical manifestations.3 Although these classification 
criteria were designed for research purposes, they are used in 
clinical practice for diagnosing APS. To confirm the diagnosis 
of a patient who presents with ischemic stroke and aPL posi-
tivity as definite APS, the positivity and titer of aPL are serially 
checked. However, the clinical relevance of persistence and me-
dium to high titers of aPL has not yet been identified.
The prevalence of aPL in a healthy population was reported 
to be 8% for lupus anticoagulant (LA), 6.5% for immunoglob-
ulin G (IgG) aCL, and 9.4% for IgM aCL in cross-sectional stud-
ies,4,5 whereas that of persistent aPL positivity was <2% in nor-
mal subjects who were initially found to have aCL. Moreover, 
in 522 healthy blood donors who were incidentally found to 
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Purpose: International consensus criteria for antiphospholipid syndrome (APS) require persistently positive antiphospholipid 
antibodies (aPL) and medium or high titers in association with clinical manifestations. However, the clinical relevance of persis-
tence and titers of aPL in patients with stroke has not been identified. We aimed to investigate the risk of subsequent thrombotic 
events in patients with ischemic stroke with aPL positivity in terms of aPL status.
Materials and Methods: We reviewed the medical records of 99 patients with ischemic stroke with at least one or more aPL-positivity 
(i.e., positivity for aCL, anti-β2-glycoprotein-1, and/or lupus anticoagulants). The patients were divided into two groups: “definite APS” 
who fulfilled the laboratory criteria and “indefinite APS” who fell short of the criteria. We compared the risk of subsequent throm-
botic events between the two groups. Cox proportional hazards model and Kaplan-Meier survival curves were used for the analyses.
Results: Of the 99 patients, 46 (46%) were classified as having definite APS and 53 (54%) as having indefinite APS. The mean fol-
low-up was 51.6 months. Overall event numbers were 14 (30.4%) in definite APS and 16 (30.2%) in indefinite APS. Increased subse-
quent thrombotic events (hazard ratio 1.039; 95% confidence interval 0.449−2.404; p=0.930) and decreased time to thrombotic events 
(log-rank p=0.321) were not associated with aPL status.
Conclusion: There was no increased risk of subsequent thrombotic events in ischemic stroke patients with definite APS, compared 
with those with indefinite APS.
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have aCL, no thrombotic events were found.5 However, per-
sistent aPL positivity was more strongly associated with throm-
botic events than transient aPL positivity.6 These findings im-
ply the importance of the persistence of aPL. Nevertheless, the 
clinical implications of transient aPL positivity on the clinical 
progress of patients with ischemic stroke are uncertain.
Questions also remain concerning titers of aPL, as there are 
conflicting data. There are studies demonstrating that a mod-
erate to high titer of aCL is more strongly associated with vas-
cular thrombosis. High titers (>40 U) of aCL confer increased 
risk for subsequent thrombo-occlusive events after cerebral 
ischemia, compared with low titers (<40 U).7 Ruffatti, et al.8 
showed medium to high titers of aCL to be a risk factor for th-
rombotic events in asymptomatic aPL carriers. On the other 
hand, there was a study showing that high titers of aCL caused 
no difference in the vascular and pregnancy risk, compared with 
moderate titers of aCL.9 Furthermore, comparing low titers with 
moderate to high titers of aPL showed no differences in vascu-
lar and obstetric events.10-12
In a systematic review, a significant association between aPL 
and cerebrovascular events was noted, with a cumulative odds 
ratio of 5.48 [95% confidence interval (CI) 4.42−6.79];13 how-
ever, the risk of recurrence of thrombosis associated with aPL 
after the first episode of a cerebrovascular event is not well de-
fined.14 The Antiphospholipid Antibodies and Stroke Study 
(APASS), a prospective cohort study within the Warfarin Aspi-
rin Recurrent Stroke Study (WARSS), showed that the pres-
ence of either LA or aCL did not predict subsequent throm-
botic events after the first ischemic stroke.15 In this study, aPL 
status was measured only once before randomization, and low 
titers of aCL were included. Moreover, anti-β2-GP1 was not 
included in the evaluation of aPL status. These features did 
not satisfy the current diagnostic criteria; therefore, they could 
not verify the implication of persistence or low/high titer of aPL 
on the risk of recurrent thrombosis.
The treatment recommendations for patients with ischemic 
stroke with aPL are based on APASS data, which revealed that 
warfarin and aspirin appear to be equivalent for subsequent 
thrombosis events after the first episode of ischemic stroke with 
aPL.15 These differ from the treatment recommendations for 
patients with venous thrombosis and aPL, which is to start life-
long anticoagulation therapy to prevent recurrent thrombosis.16 
However, as mentioned earlier, the APASS population is not 
confined to definite APS criteria; hence, the optimal treatment 
of patients with ischemic stroke who satisfy the definite APS 
criteria is controversial.
The aim of this study was to investigate the risk of subse-
quent thrombotic events in patients with ischemic stroke with 
aPL positivity in terms of aPL status. Furthermore, we compared 
the recurrence rate of thrombosis between patients treated 
with antiplatelets and those treated with anticoagulants.
MATERIALS AND METHODS
Patients
We collected the data of 99 patients with ischemic stroke who 
had at least one or more aPL-positive result (i.e., positivity for 
aCL, anti-β2-GPI, and LA antibodies) who presented to Yonsei 
University Health System, Severance Hospital. We extracted 
the data using the clinical data retrieval system and reviewed 
the medical records of patients (Supplementary Fig. 1, only on-
line). To address the issue of the effect of persistent and medi-
um- or high-titer of aPL on the risk of recurrence of thrombo-
sis, we classified the 99 patients into two groups according to 
whether they satisfy the laboratory criteria for APS. According 
to laboratory criteria for APS regarding revised Sapporo clas-
sification criteria, the patients should have medium- or high-
titers of aPL on two or more occasions at least 12 weeks apart.3 
Forty-six of 99 (46.5%) patients were classified as having “defi-
nite APS,” meaning that they met the laboratory criteria for APS 
along with a clinical history of stroke. Fifty-three of 99 (53.5%) 
patients were classified as having “indefinite APS,” meaning 
that they have a clinical history of stroke and aPL positivity, but 
fell short of the laboratory criteria for APS.
Subgroup analysis
We subtracted 19 patients whose aPL was checked only once. 
We divided the remaining 80 patients whose aPL was checked 
more than twice into two groups: 13 of 80 (16.3%) were classi-
fied as “patients with transient aPL,” defined as patients who 
had a positive aPL result only once; 67 of 80 (83.7%) were clas-
sified as “patients with persistent aPL,” defined as patients who 
had a positive aPL result more than two times.
Furthermore, we evaluated the number of aPL-positive cat-
egories (aCL, β2-GPI, and LA) at each time and classified the 
patients into two subgroups according to the variation of aPL-
positive categories. “Patients with increasing variety of aPL” 
were defined as patients whose number of aPL-positive catego-
ries had increased during the follow-up period, whereas “pa-
tients with decreasing variety of aPL” were defined as those 
whose number of aPL-positive categories had decreased dur-
ing the follow-up. We compared these two subgroups with pa-
tients whose number of aPL-positive categories had not been 
increased or decreased to analyze the influence of aPL patterns 
on the outcome.
Data collection
The following parameters were reviewed: 1) demographic 
data (age and sex); 2) vascular risk factors (hypertension, dia-
betes mellitus, cholesterol levels, cardiac valvulopathy, arrhyth-
mia, coronary arterial disease, prior pregnancy morbidity, 
and smoking status); 3) follow-up duration since the first epi-
sode of stroke or TIA and the time to recurrence; 4) treatment 
with antiplatelets or anticoagulants; 5) duration of anticoagu-
lation, if received; and 6) mean international normalized ratio 
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(INR) in patients with anticoagulation.
aPL assays
We checked the IgM and IgG isotypes of aCL and the IgM and 
IgG isotypes of anti-β2-GPI and LA.
The serum levels of both aCL and anti-β2-GPI were mea-
sured by using an automated fluorescence enzyme immuno-
assay (EliA; Phadia, Freiburg, Germany) according to the man-
ufacturer’s instructions. We used the Sydney criteria cut-off of 
>40 GPL/MPL units for medium or high titers of aCL IgG and 
IgM for patients with definite APS. The cut-off values for posi-
tivity of aCL IgG and IgM, we used 10 GPL/MPL units as pro-
posed by the manufacturer. As there is no proposed Sydney cri-
teria cut-off for anti-β2-GP1, we used the 99th percentile cut-
off for anti-β2-GP1 for patients with definite APS, which was 
18 U/mL for IgG and 7 U/mL for IgM. The cut-off values for pos-
itivity of anti-β2-GP1 IgG and IgM were 7 U/mL as suggested 
by the manufacturer.
LA testing was performed as follows. Peripheral blood sam-
ples were collected in 3.2% sodium citrate tubes, and platelet-
poor plasma (validated by using a platelet count of <10×109/L) 
was obtained through double centrifugation for 15 min at 
1500 rcf and 15 min at 2500 rcf at room temperature. Both sc-
reening and confirmatory tests for LA were conducted on an 
ACL TOP 700 coagulation analyzer (Instrumentation Labora-
tory, Milan, Italy) with an assay kit utilizing diluted Russell’s 
viper venom (HemosIL Diluted Russell’s Viper Venom Time 
Screen/Confirm kit, Instrumentation Laboratory). Initially, sc-
reening tests were conducted, and the samples with test re-
sults within normal ranges, defined as screening ratio [patient 
screening result (sec)/mean of normal screening range (sec)] 
<1.2, were reported as “negative.” Those with screening results 
exceeding normal ranges were subjected to a confirmatory test, 
and the results from the confirmatory test were compared with 
the screening result to deduce the normalized ratio as follows:
Patient screening (sec)/ 
mean of normal screening range (sec)
Patient confirmatory (sec)/ 
mean of normal confirmatory range (sec)
The results of the confirmatory test were reported according 
to the normalized ratio as follows: <1.2, LA negative; 1.2−1.5, 
LA weakly positive; and >1.5, LA positive.
Statistical analysis 
All statistical analyses were performed with IBM SPSS soft-
ware, version 23.0 (IBM Corp., Armonk, NY, USA). Categorical 
data are expressed as absolute and relative frequencies, and 
continuous data are presented as mean±standard deviation. 
The group differences were assessed by using the t-test for con-
tinuous variables, and the chi-square test or Fisher’s exact test 
for categorical variables. The Kaplan-Meier survival method 
with log-rank test was used to assess the association of the 
time to thrombotic events and aPL status. Furthermore, uni-
variate and multivariate Cox proportional hazard models were 
applied to determine the predictive value and to adjust for 
variables that were imbalanced and other potential confound-
ers, including traditional stroke risk factors. A p-value of <0.05 
was considered significant.
RESULTS
Comparison of baseline variables between patients 
with definite APS and those with indefinite APS
The mean age at the first event of ischemic stroke or TIA was 
43.6 years, and there was no difference between patients with 
definite APS and those with indefinite APS. The mean follow-
up duration was 51.6 months, and patients with definite APS 
were followed longer, although there was no statistical signifi-
cance. The group with definite APS had a higher proportion of 
female patients and a lower incidence of comorbid diabetes 
mellitus than the group with indefinite APS. There were no dif-
ferences in the presence of hypertension, history of cigarette 
smoking, prior cardiovascular diseases such as myocardial in-
farction or peripheral arterial occlusive diseases, combined 
cardiac diseases including cardiac valvulopathy, arrhythmia, 
coronary arterial disease, and prior pregnancy morbidity be-
tween the two groups. Nine patients among patients with def-
inite APS and 1 patient among patients with indefinite APS had 
concomitant systemic lupus erythematosus (SLE). The baseline 
total cholesterol, triglyceride, high-density lipoproteins, and 
low-density lipoproteins showed no statistical differences. 
Among patients with definite APS, 9 patients (19.6%) were on 
aspirin, 3 patients (6.5%) were on clopidogrel, 10 patients 
(21.7%) were on aspirin+clopidogrel, 21 patients (45.7%) were 
on warfarin, and 3 patients (6.5%) were on warfarin+aspirin. 
Among patients with indefinite APS, 12 patients (23.1%) were 
on aspirin, 8 patients (15.4%) were on clopidogrel, 3 patients 
(5.8%) were on cilostazol, 15 patients (28.8%) were on aspi-
rin+clopidogrel, 13 patients (25.0%) were on warfarin, and 1 
patient (1.9%) was on warfarin+aspirin. Patients with definite 
APS were more frequently on anticoagulation therapy than those 
with indefinite APS (52.2% for definite APS vs. 26.9% for in-
definite APS, p=0.010), whereas patients with indefinite APS 
were more frequently on antiplatelet therapy than those with 
indefinite APS (54.3% for definite APS vs. 75.0% for indefinite 
APS, p=0.032) (Table 1).
Additionally, we compared the baseline clinical character-
istics between the patients with or without recurrent thrombot-
ic events regardless of definite or indefinite APS for more in-
formation (Supplementary Table 1, only online). 
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Comparison of subsequent thrombotic events 
between patients with definite APS and those with 
indefinite APS
Table 2 shows the subsequent thrombotic event outcomes in 
patients with definite APS and those with indefinite APS. Re-
current ischemic stroke was the most common thrombotic 
event, which is consistent with previous studies indicating that 
recurrent thrombotic event occurs in the same vascular beds.
There was no increased risk of any subsequent thrombotic 
events, including ischemic stroke, TIA, myocardial infarction, 
pulmonary thromboembolism, deep vein thrombosis, and 
peripheral arterial occlusive diseases in patients with definite 
APS, compared with those with indefinite APS (30.4% for defi-
nite APS vs. 30.2% for indefinite APS, p=0.979).
There were no differences in the time to any thrombotic ev-
ents between patients with definite APS and those with indef-
inite APS (log-rank p=0.321) (Fig. 1). After adjusting for con-
founders that showed imbalance between the two groups 
(Cox proportional hazard model), including sex, comorbid dia-
betes mellitus, comorbid SLE, history of anticoagulation, and 
antiplatelet agent, there was no increased risk of subsequent 
thrombotic events associated with definite APS, compared with 
Table 1. Baseline Characteristics of the Study Group
Variables Definite APS (n=46) Indefinite APS (n=53) Total (n=99) p value
First attack age (yr)   44.0±13.0   43.2±13.8   43.6±13.4 0.758
Female sex, n (%) 28 (60.9) 19 (35.8) 47 (47.5) 0.013
F/U duration (month)   60.4±53.3   43.8±39.2   51.6±46.8 0.078
Hypertension, n (%) 12 (26.1) 18 (34.0) 30 (30.3) 0.511
Diabetes mellitus, n (%) 2 (4.3) 11 (20.8) 13 (13.1) 0.016
Smoking, ever done, n (%) 15 (32.6) 23 (43.4) 38 (38.4) 0.271
Smoking (pack-years)     7.7±13.2     9.9±16.1     8.9±14.8 0.458
Prior CVD, n (%) 0 (0) 1 (1.9) 1 (1.0) 0.349
Cardiac diseases, n (%)   6 (13.0) 13 (24.5) 19 (19.2) 0.148
aCL IgG, GPL units   32.8±51.6     6.1±14.3   18.1±38.3 0.002
aCL IgM, MPL units   16.7±36.0   6.9±9.9   11.3±25.5 0.090
anti-β2-GP1 IgG (U/mL)   26.9±50.9   10.5±56.3   17.7±54.3 0.188
anti-β2-GP1 IgM (U/mL)   22.3±49.1     9.5±34.0   15.0±41.5 0.177
LA (+), n (%) 26 (57.8) 18 (35.3) 44 (45.8) 0.027
SLE, n (%)   9 (19.6) 1 (1.9) 10 (10.2) 0.004
Other autoimmune diseases 1 (2.2) (BD) 2 (3.8) (SjS, SSc) 3 (3.0) 0.553
Abortion history, n (%)*   4 (21.1)   4 (14.8)   8 (17.4) 0.834
Antiplatelet therapy, n (%) 25 (54.3) 39 (75.0) 64 (65.3) 0.032
Anticoagulation therapy, n (%) 24 (52.2) 14 (26.9) 38 (38.8) 0.010
Total cholesterol (mg/dL) 175.5±43.8 183.1±45.1 179.6±44.5 0.400
Triglyceride (mg/dL)   121.6±100.2   152.7±142.3   138.0±124.5 0.231
HDL-cholesterol (mg/dL)   42.8±14.2   43.5±10.4   43.2±12.3 0.764
LDL-cholesterol (mg/dL) 105.8±28.8 105.2±33.2 105.5±31.1 0.923
APS, antiphospholipid syndrome; F/U, follow-up; CVD, cardiovascular disease; aCL, anticardiolipin antibody; anti-β2-GP1, anti-β2-glycoprotein-1 antibody; LA, 
lupus anticoagulant; SLE, systemic lupus erythematosus; HDL, high density lipoprotein; LDL, low density lipoprotein; BD, Behçet’s disease; SjS, Sjögren’s syn-
drome; SSc, systemic sclerosis.
Values are expressed as mean±standard deviation or n (%). 
*Percentage is calculated only among females.
Table 2. Subsequent Thrombotic Events According to Definite and Indefinite APS
Thrombotic events Definite APS (n=46) Indefinite APS (n=53) Total (n=99) p value
Ischemic stroke, n (%) 12 (26.1) 14 (26.4) 26 (26.3) 0.970
TIA, n (%) 1 (2.2) 1 (1.9) 2 (2.0) 1.000
MI, n (%) 0 3 (5.7) 3 (3.0) 0.246
PTE, n (%) 1 (2.2) 0 1 (1.0) 0.465
DVT, n (%) 1 (2.2) 0 1 (1.0) 0.465
PAOD, n (%) 2 (4.3) 0 2 (2.0) 0.213
Any thrombotic events (%) 14 (30.4) 16 (30.2) 30 (30.3) 0.979
APS, antiphospholipid syndrome; TIA, transient ischemic attack; MI, myocardial infarction; PTE, pulmonary thromboembolism; DVT, deep vein thrombosis; PAOD, pe-
ripheral arterial occlusive disease.
1132
Recurrence in Ischemic Stroke with aPL
https://doi.org/10.3349/ymj.2017.58.6.1128
indefinite APS [hazard ratio (HR) 1.039, 95% CI 0.449−2.404; 
p=0.930].
Comparison of subsequent thrombotic events 
according to aPL status in subgroup analysis
Subgroup analysis on the influence of persistence of aPL on the 
risk of subsequent thrombotic events was done. Thirteen pa-
tients with transient aPL had five events (38.5%) and 67 patients 
with persistent aPL had 18 events (26.9%), indicating that per-
sistent aPL did not increase the risk of subsequent thrombosis 
in patients with stroke (log-rank p=0.311) (Fig. 2).
There were 13 patients with increasing variety of aPL and 22 
patients with decreasing variety of aPL. Five patients among 
those with increasing variety of aPL had subsequent throm-
botic events. When compared with patients without increasing 
variety of aPL, there were no differences in the risk of subse-
quent thrombotic events (38.5% vs. 24.1%; HR 1.724, 95% CI 
0.603−4.930; p=0.310) (Table 3). Nine patients among those with 
decreasing variety of aPL had thrombotic events, which had 
no differences from patients without decreasing variety of aPL 
(40.9% vs. 24.1%; adjusted HR 1.214, 95% CI 0.512−2.882; 
p=0.660) (Table 4).
Also, we analyzed the effect of single, double, and triple posi-
tivity on subsequent thrombotic events. Among our total 99 
study population, 55 patients had single positivity for aPL, 27 
patients had double positivity for aPL, and 17 patients had tri-
ple positivity for aPL. There were no differences in the time to 
any thrombotic events between patients with single, double, 
and triple positivity for aPL (26.3% for single positivity vs. 40.7% 
for double positivity vs. 35.3% for triple positivity; log-rank p= 
0.922) (Fig. 3). 
Comparison of subsequent thrombotic events with 
regard to treatment modality among patients with 
definite APS
About half of the patients with definite APS were receiving an-
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Fig. 1. Kaplan-Meier analysis of time to thrombotic events according to 
definite and indefinite APS. APS, antiphospholipid syndrome.
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Fig. 2. Kaplan-Meier analysis of time to thrombotic events according to 
transient and persistent aPL positivity. aPL, antiphospholipid antibodies.
Table 3. Subsequent Thrombotic Events According to aPL Status
Increasing aPL 
(n=13)
Without increasing aPL 
(n=54)
Unadjusted
HR (95% CI) p value
Recurrence any thrombotic event 5 (38.5%) 13 (24.1%) 1.724 (0.603–4.930) 0.310
aPL, antiphospholipid antibodies; HR, hazard ratio; CI, confidence interval.
Cox proportional hazard model for subsequent thrombotic events according to increasing variety of aPL.
Table 4. Subsequent Thrombotic Events According to aPL Status
 
Decreasing aPL 
(n=22)
Without decreasing aPL 
(n=58)
Unadjusted Adjusted
HR (95% CI) p value HR (95% CI) p value
Recurrence any TOE 9 (40.9%) 14 (24.1%) 1.566 (0.676–3.627) 0.295 1.214 (0.512–2.882) 0.660*
aPL, antiphospholipid antibodies; HR, hazard ratio; CI, confidence interval; TOE, thrombo-occlusive events.
Cox proportional hazard model for subsequent thrombotic events according to decreasing variety of aPL (*Adjusted for comorbid cardiac diseases. This covariate 
was included in the model owing to an imbalance between the two groups).
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Fig. 3. Kaplan-Meier analysis of thrombotic events according to single, 
double, and triple positivity for antiphospholipid antibodies.
Table 5. Comparison of Subsequent Thrombotic Events According to Antiplatelet Therapy/Anticoagulation among Patients with Definite APS
 
 Antiplatelet agent 
(n = 22)
Anticoagulation 
(n = 24)
Total 
(n = 46)
Unadjusted
HR (95% CI) p value
Recurrence of any thrombotic events 6 (27.3%) 8 (33.3%) 14 (30.4%) 0.992 (0.341–2.891) 0.989
APS, antiphospholipid syndrome; HR, hazard ratio; CI, confidence interval.
ticoagulation, and the other half were receiving an antiplatelet 
agent without anticoagulation. To evaluate the outcome ac-
cording to treatment modality, we divided the patients with 
definite APS into two groups: 24 patients who were receiving 
anticoagulants and 22 patients who were receiving an anti-
platelet agent only without anticoagulation. Three patients 
were receiving anticoagulants combined with antiplatelet 
agent, which we classified as the anticoagulants group. Six pa-
tients among those who were receiving an antiplatelet agent 
only and eight patients who were receiving anticoagulation had 
recurrent thrombotic events. There was no increased risk of re-
currence depending on the treatment modality (27.3% vs. 33.3%; 
HR 0.992, 95% CI 0.341−2.891; p=0.989) (Table 5). The mean INR 
was 2.0 in patients who were receiving anticoagulation, and 
there was no difference in the INR between patients with and 
without recurrence.
DISCUSSION
We observed subsequent thrombotic outcomes in 99 patients 
who had been diagnosed as having ischemic stroke with aPL 
positivity at a single institution. We divided the patients into 
two groups by applying the APS criteria to reflect the effect of 
the persistence and titers of aPL and followed the patients for 
a mean of 51.6 months. There was no increased risk of subse-
quent thrombotic events after the first ischemic stroke accord-
ing aPL status.
Satisfying the laboratory criteria for APS did not increase the 
risk of subsequent thrombotic events in patients with ischemic 
stroke, compared with those with aPL positivity but fell short 
of the laboratory criteria. Furthermore, there were no associa-
tions between aPL status with regard to the persistence or vari-
ation in the number of aPL and the risk of subsequent throm-
botic events. This result is consistent with a previous APASS-
WARSS study15 that showed no association between immu-
noreactivity to aPL and subsequent thrombotic events. How-
ever, the APASS-WARSS study checked aPL only once without 
considering the titers of aPL, and anti-β2-GPI was not analyzed. 
Owing to this limitation, the outcome of patients with stroke 
who fulfilled the criteria for APS was not clearly demonstrated.
Recently, a follow-up APASS-WARSS study evaluated the im-
pact of anti-β2-GPI and the persistence of aPL on recurrent 
thrombotic events.17 The authors found that persistent anti-β2-
GPI was associated with decreased time to thrombotic events; 
however, the overall event rate was not increased. Furthermore, 
the results were inconsistent with aCL, showing that having aCL 
positivity more than once was associated with a decreased 
risk of thrombotic events. In contrast, our data showed more 
consistent results showing that there were no associations be-
tween aPL and recurrent thrombotic risk, and the time to th-
rombotic event was not influenced by aPL.
Among our patients, 10 were diagnosed as having SLE, five 
of whom had underlying SLE before the first stroke event, and 
four were diagnosed as having SLE at the time of the first stroke 
event (i.e., SLE manifested with stroke). Only two patients were 
diagnosed as having an autoimmune disease after the stroke 
event during routine follow-up, one with SLE and the other with 
Sjogren’s syndrome. No other patient was newly diagnosed as 
having an autoimmune disease.
Our study population was relatively young, as the mean age 
at the first ischemic stroke event was 43.6 years, and the mean 
lipid level was within the normal range, strengthening the pos-
sibility of aPL being a major risk factor in these patients. In a sys-
temic review, the presence of aPL in young adults increased the 
risk by 5.48-fold for stroke or TIA.13,18 However, after a diagnosis 
of stroke with aPL positivity, the impact of the titers or persis-
tence of aPL on recurrence is controversial.19-22 Our data dem-
onstrate that satisfying the criteria for APS does not constitute 
a higher risk for recurrence, and aPL positivity did not predict 
future autoimmune diseases.
We first hypothesized that an increasing variety of aPL would 
increase the tendency toward a more hypercoagulable status, 
as well as the risk of recurrent thrombosis, and that decreas-
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ing aPL might confer a lower risk of recurrence. However, nei-
ther the persistence nor variation in aPL had an influence on 
the risk of recurrence, implying that variation of aPL status does 
not provide valuable information for predicting further throm-
botic events.
Although the population sample was small, we reviewed re-
currence risk according to treatment modality. About half of the 
patients with definite APS were receiving anticoagulation and 
the other half were receiving antiplatelet therapy. Anticoagu-
lation is considered to be superior to antiplatelet agents in pa-
tients with APS; however, the recurrence rate was not lower in 
patients treated with anticoagulants.
To our knowledge, this is the first study to apply the APS cri-
teria with regard to recurrence in patients with ischemic stroke. 
Moreover, we observed the implication of aPL status. Further-
more, our study was performed at a single center that provides 
consistent laboratory reports on aPL, as well as standardized 
and experienced treatment for patients.
The limitations of this study include the retrospective nature 
of data from a relatively small size of patients. Moreover, con-
cerning the LA results, it should be considered that the serial 
follow-up tests of LA were conducted after anticoagulation 
treatment, which may lead to false-positive results. Despite 
these limitations, this study demonstrated that the risk of sub-
sequent thrombotic events was similar in patients with tran-
sient or low titers of aPL, compared with those with persistent 
and medium to high titers of aPL. However, further prospec-
tive studies with greater population are needed to confirm the 
role of aPL in recurrence in patients with ischemic stroke.  
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